OBJECTIVES: To determine how patients complied with different components of guideline-recommended post-treatment surveillance in a large nationwide population-based cohort of patients with colon cancer. STUDY DESIGN: Retrospective cohort study. METHODS: We used the linked Surveillance, Epidemiology, and End Results-Medicare database to identify patients 66 years or older diagnosed as having stage I to stage III colon adenocarcinoma between January 2000 and June 2002 with a follow-up duration of at least 3.5 years. After tumor resection, patients who completed at least 2 office visits per year for 3 years, at least 2 carcinoembryonic antigen tests per year (in the first and second years of follow-up), and at least 1 colonoscopy within 3 years were defined as meeting the recommended post-treatment care. RESULTS: We identified 7348 patients, with a median follow-up duration of 59 months. Adherence to post-treatment surveillance was 83.9% for office visits, 29.4% for carcinoembryonic antigen tests, and 74.3% for colonoscopy. Younger age at diagnosis, white race/ethnicity, married status, advanced tumor stage, fewer comorbidities, and chemotherapy use were significantly associated with guideline adherence. CONCLUSIONS: Adherence to colon cancer posttreatment surveillance was low, although proportions of patients complying with office visits and colonoscopy were reasonably high. Underlying reasons for noncompliance, which varied by type of service, may need further investigation.
OBJECTIVES: To determine how patients complied with different components of guideline-recommended post-treatment surveillance in a large nationwide population-based cohort of patients with colon cancer. STUDY DESIGN: Retrospective cohort study. METHODS: We used the linked Surveillance, Epidemiology, and End Results-Medicare database to identify patients 66 years or older diagnosed as having stage I to stage III colon adenocarcinoma between January 2000 and June 2002 with a follow-up duration of at least 3.5 years. After tumor resection, patients who completed at least 2 office visits per year for 3 years, at least 2 carcinoembryonic antigen tests per year (in the first and second years of follow-up), and at least 1 colonoscopy within 3 years were defined as meeting the recommended post-treatment care. RESULTS: We identified 7348 patients, with a median follow-up duration of 59 months. Adherence to post-treatment surveillance was 83.9% for office visits, 29.4% for carcinoembryonic antigen tests, and 74.3% for colonoscopy. Younger age at diagnosis, white race/ethnicity, married status, advanced tumor stage, fewer comorbidities, and chemotherapy use were significantly associated with guideline adherence. CONCLUSIONS: Adherence to colon cancer posttreatment surveillance was low, although proportions of patients complying with office visits and colonoscopy were reasonably high. Underlying reasons for noncompliance, which varied by type of service, may need further investigation.
Authors: Stephen S Grubbs; Blase N Polite; John Carney; William Bowser; Jill Rogers; Nora Katurakes; Paula Hess; Electra D Paskett Journal: J Clin Oncol Date: 2013-04-15 Impact factor: 44.544
Authors: Daisy Le; Cheryl L Holt; Maria Pisu; Aquila Brown-Galvan; Temeika L Fairley; Judith Lee Smith; Arica White; Ingrid J Hall; Robert A Oster; Michelle Y Martin Journal: J Psychosoc Oncol Date: 2014
Authors: Maria Pisu; Cheryl L Holt; Aquila Brown-Galvan; Temeika Fairley; Judith Lee Smith; Arica White; Ingrid J Hall; Robert A Oster; Michelle Y Martin Journal: J Oncol Pract Date: 2014-01-02 Impact factor: 3.840
Authors: Steven T Fleming; Heath B Mackley; Fabian Camacho; Eric E Seiber; Niraj J Gusani; Stephen A Matthews; Jason Liao; Tse-Chuan Yang; Wenke Hwang; Nengliang Yao Journal: J Rural Health Date: 2013-06-26 Impact factor: 4.333
Authors: E Carter Paulson; Christine M Veenstra; Anil Vachani; Christine A Ciunci; Andrew J Epstein Journal: Cancer Date: 2015-06-16 Impact factor: 6.860
Authors: Melissa Y Carpentier; Sally W Vernon; L Kay Bartholomew; Caitlin C Murphy; Shirley M Bluethmann Journal: J Cancer Surviv Date: 2013-05-16 Impact factor: 4.442
Authors: Talya Salz; Shrujal S Baxi; Victoria S Blinder; Elena B Elkin; Margaret M Kemeny; Mary S McCabe; Chaya S Moskowitz; Erin E Onstad; Leonard B Saltz; Larissa K F Temple; Kevin C Oeffinger Journal: J Oncol Pract Date: 2014-06-03 Impact factor: 3.840
Authors: Leah M Backhus; Farhood Farjah; Steven B Zeliadt; Thomas K Varghese; Aaron Cheng; Larry Kessler; David H Au; David R Flum Journal: Ann Thorac Surg Date: 2014-10-03 Impact factor: 4.330